20 results on '"Loveman, C."'
Search Results
2. PUK26 - Burden On Secondary Care Of Overactive Bladder Patients Who Are Inadequately Managed With Anticholinergics In England
3. PUK8 - An Economic Model To Investigate The Budget Impact In Spain Of Onabotulinumtoxina To Manage Urinary Incontinence In Patients With Idiopathic Overactive Bladder
4. PUK21 - A Cost-Effectiveness Analysis Of Onabotulinumtoxina Verse. Best Supportive Care (bsc) For The Treatment Of Anticholinergic Treatment-Refractory Neurogenic Detrusor Overactivity (ndo)
5. PUK22 - Cost-Effectiveness Comparison Of Botulinum Toxin Type A Plus Best Supportive Care Versus Best Supportive Care Alone In The Treatment Of Idiopathic Overactive Bladder With Urinary Incontinence Among Patients Not Adequately Managed By Anticholinergic Therapy In France
6. 701 Cost-utility analysis of onabotulinumtoxinA versus best supportive care in the treatment of idiopathic overactive bladder with urinary incontinence among patients not adequately managed with anticholinergic therapy
7. 582 An economic model to investigate differences in resource utilisation associated with the use of BOTOX® to manage urinary incontinence in patients with idiopathic overactive bladder in the United Kingdom
8. PUK8 An Economic Model To Investigate The Budget Impact In Spain Of Onabotulinumtoxina To Manage Urinary Incontinence In Patients With Idiopathic Overactive Bladder
9. PUK22 Cost-Effectiveness Comparison Of Botulinum Toxin Type A Plus Best Supportive Care Versus Best Supportive Care Alone In The Treatment Of Idiopathic Overactive Bladder With Urinary Incontinence Among Patients Not Adequately Managed By Anticholinergic Therapy In France
10. PUK21 A Cost-Effectiveness Analysis Of Onabotulinumtoxina Verse. Best Supportive Care (bsc) For The Treatment Of Anticholinergic Treatment-Refractory Neurogenic Detrusor Overactivity (ndo)
11. A Cost-Effectiveness Analysis Of Onabotulinumtoxina Verse. Best Supportive Care (bsc) For The Treatment Of Anticholinergic Treatment-Refractory Neurogenic Detrusor Overactivity (ndo).
12. Burden On Secondary Care Of Overactive Bladder Patients Who Are Inadequately Managed With Anticholinergics In England.
13. Cost-Effectiveness Comparison Of Botulinum Toxin Type A Plus Best Supportive Care Versus Best Supportive Care Alone In The Treatment Of Idiopathic Overactive Bladder With Urinary Incontinence Among Patients Not Adequately Managed By Anticholinergic Therapy In France.
14. An Economic Model To Investigate The Budget Impact In Spain Of Onabotulinumtoxina To Manage Urinary Incontinence In Patients With Idiopathic Overactive Bladder.
15. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.
16. Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison.
17. Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective.
18. Differences in family functioning among bulimics, repeat dieters, and nondieters.
19. REPARATIVE GIANT-CELL GRANULOMA.
20. Postextraction acute cellulitis caused by Salmonella choleraesuis: report of case.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.